These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 8315430

  • 1. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy.
    Weaver CH, Appelbaum FR, Petersen FB, Clift R, Singer J, Press O, Bensinger W, Bianco J, Martin P, Anasetti C.
    J Clin Oncol; 1993 Jul; 11(7):1329-35. PubMed ID: 8315430
    [Abstract] [Full Text] [Related]

  • 2. High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy.
    Demirer T, Weaver CH, Buckner CD, Petersen FB, Bensinger WI, Sanders J, Clift RA, Lilleby K, Anasetti C, Martin P.
    J Clin Oncol; 1995 Mar; 13(3):596-602. PubMed ID: 7884421
    [Abstract] [Full Text] [Related]

  • 3. Carmustine, Ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: a dose-finding study.
    Snyder MJ, Johnson DB, Daly MB, Giguere JK, Harman GH, Harden EA, Johnson RA, Leff RS, Mercier RJ, Messerschmidt GL.
    Bone Marrow Transplant; 1994 Oct; 14(4):595-600. PubMed ID: 7858534
    [Abstract] [Full Text] [Related]

  • 4. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.
    Wheeler C, Antin JH, Churchill WH, Come SE, Smith BR, Bubley GJ, Rosenthal DS, Rappaport JM, Ault KA, Schnipper LE.
    J Clin Oncol; 1990 Apr; 8(4):648-56. PubMed ID: 2313334
    [Abstract] [Full Text] [Related]

  • 5. High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma.
    Lazarus HM, Crilley P, Ciobanu N, Creger RJ, Fox RM, Shina DC, Bulova SI, Gucalp R, Cooper BW, Topolsky D.
    J Clin Oncol; 1992 Nov; 10(11):1682-9. PubMed ID: 1403051
    [Abstract] [Full Text] [Related]

  • 6. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Reece DE, Barnett MJ, Connors JM, Fairey RN, Fay JW, Greer JP, Herzig GP, Herzig RH, Klingemann HG, LeMaistre CF.
    J Clin Oncol; 1991 Oct; 9(10):1871-9. PubMed ID: 1919637
    [Abstract] [Full Text] [Related]

  • 7. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies.
    Stahel RA, Jost LM, Cerny T, Pichert G, Honegger H, Tobler A, Jacky E, Fey M, Platzer E.
    J Clin Oncol; 1994 Sep; 12(9):1931-8. PubMed ID: 7521907
    [Abstract] [Full Text] [Related]

  • 8. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Jagannath S, Armitage JO, Dicke KA, Tucker SL, Velasquez WS, Smith K, Vaughan WP, Kessinger A, Horwitz LJ, Hagemeister FB.
    J Clin Oncol; 1989 Feb; 7(2):179-85. PubMed ID: 2644397
    [Abstract] [Full Text] [Related]

  • 9. Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.
    Adkins DR, Salzman D, Boldt D, Kuhn J, Irvin R, Roodman GD, Lyons R, Smith L, Freytes CO, LeMaistre CF.
    J Clin Oncol; 1994 Sep; 12(9):1890-901. PubMed ID: 7916039
    [Abstract] [Full Text] [Related]

  • 10. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
    Wheeler C, Khurshid A, Ibrahim J, Elias A, Mauch P, Ault K, Antin J.
    Leuk Lymphoma; 2001 Feb; 40(5-6):499-509. PubMed ID: 11426523
    [Abstract] [Full Text] [Related]

  • 11. Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt's lymphomas in adult patients.
    Jost LM, Jacky E, Dommann-Scherrer C, Honegger HP, Maurer R, Sauter C, Stahel RA.
    Ann Oncol; 1995 May; 6(5):445-51. PubMed ID: 7545428
    [Abstract] [Full Text] [Related]

  • 12. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease.
    Vose JM, Sharp G, Chan WC, Nichols C, Loh K, Inwards D, Rifkin R, Bierman PJ, Lynch JC, Weisenburger DD, Kessinger A, Armitage JO.
    J Clin Oncol; 2002 May 01; 20(9):2344-52. PubMed ID: 11981006
    [Abstract] [Full Text] [Related]

  • 13. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.
    van Besien K, Tabocoff J, Rodriguez M, Andersson B, Mehra R, Przepiorka D, Dimopoulos M, Giralt S, Suki S, Khouri I.
    Bone Marrow Transplant; 1995 Apr 01; 15(4):549-55. PubMed ID: 7655380
    [Abstract] [Full Text] [Related]

  • 14. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide.
    Wheeler C, Strawderman M, Ayash L, Churchill WH, Bierer BE, Elias A, Gilliland DG, Antman K, Guinan EC, Eder JP.
    J Clin Oncol; 1993 Jun 01; 11(6):1085-91. PubMed ID: 8099120
    [Abstract] [Full Text] [Related]

  • 15. Comparison of preparative transplantation regimens using carmustine/etoposide/cisplatin or busulfan/etoposide/cyclophosphamide in lymphoid malignancies.
    Crilley P, Lazarus H, Topolsky D, Ciobanu N, Creger RJ, Fox RM, Bulova SI, Shina DC, Gucalp R, Cooper BW.
    Semin Oncol; 1993 Aug 01; 20(4 Suppl 4):50-4; quiz 55. PubMed ID: 8342076
    [Abstract] [Full Text] [Related]

  • 16. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
    Law LY, Horning SJ, Wong RM, Johnston LJ, Laport GG, Lowsky R, Shizuru JA, Blume KG, Negrin RS, Stockerl-Goldstein KE.
    Biol Blood Marrow Transplant; 2006 Jul 01; 12(7):703-11. PubMed ID: 16785059
    [Abstract] [Full Text] [Related]

  • 17. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study.
    Martelli M, Vignetti M, Zinzani PL, Gherlinzoni F, Meloni G, Fiacchini M, De Sanctis V, Papa G, Martelli MF, Calabresi F, Tura S, Mandelli F.
    J Clin Oncol; 1996 Feb 01; 14(2):534-42. PubMed ID: 8636768
    [Abstract] [Full Text] [Related]

  • 18. [High dose chemoradiotherapy and autologous bone marrow transplantation (ABMT) as a first line therapy to treat advanced adult high-grade malignant T-cell non-Hodgkin's lymphoma--a pilot clinical study].
    Wu GQ.
    Zhonghua Zhong Liu Za Zhi; 1993 Jan 01; 15(1):47-51. PubMed ID: 7687533
    [Abstract] [Full Text] [Related]

  • 19. Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation.
    Attal M, Canal P, Schlaifer D, Chatelut E, Dezeuze A, Huguet F, Payen C, Pris J, Laurent G.
    J Clin Oncol; 1994 Jan 01; 12(1):141-8. PubMed ID: 8270970
    [Abstract] [Full Text] [Related]

  • 20. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.
    Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH.
    J Clin Oncol; 1995 Mar 01; 13(3):588-95. PubMed ID: 7884420
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.